Key result
Every 1 kg/m2 increase in body mass index was associated with a 12% increased risk of bleeding in elderly patients with non-valvular atrial fibrillation treated with dabigatran.
Why the study?
Uncertainty remains regarding the association between body mass index and bleeding risk in patients with non-valvular atrial fibrillation.
Is body mass index associated with the risk of bleeding in elderly patients with non-valvular atrial fibrillation taking dabigatran?
Cohort (n=509)
Yes
Is body mass index associated with the risk of bleeding in elderly patients with non-valvular atrial fibrillation taking dabigatran?
Higher body mass index is associated with an increased risk of bleeding in elderly patients with non-valvular atrial fibrillation treated with dabigatran.
Answers are grounded in this paper and cite their sources.
May warrant BMI-informed bleeding vigilance in elderly NVAF on dabigatran; leaves open causality and prospective validation.
BACKGROUND: Uncertainty remains regarding the association between body mass index (BMI) and the risk of bleeding in patients with non-valvular atrial fibrillation (NVAF). We aimed to investigate the association between BMI and the risk of bleeding in elderly NVAF patients taking dabigatran. METHODS: A total of 509 elderly NVAF patients, who were being treated at twelve centers in China from February 2015 to December 2017 and taking dabigatran, were analyzed. The exposure and outcome variables were BMI at baseline and bleeding events within the subsequent six months, respectively. Cox proportional hazards regression analysis was used to evaluate the association between BMI and the risk of bleeding. Moreover, the Cox proportional hazards regression with cubic spline functions and smooth curve fitting was conducted. CONCLUSIONS: BMI was significantly and positively associated with the risk of bleeding in elderly NVAF patients treated with dabigatran.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) conducted a cohort in Non-valvular atrial fibrillation (n=509). Body mass index (BMI) vs. Lower BMI was evaluated on Bleeding events within six months (HR 1.12, 95% CI 1.02-1.24, p=0.021). Every 1 kg/m2 increase in body mass index was associated with a 12% increased risk of bleeding in elderly patients with non-valvular atrial fibrillation treated with dabigatran.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: